Tech Company Financing Transactions
Myosana Therapeutics Funding Round
Myosana Therapeutics, based in Seattle, secured $1 million in funding from CureDuchenne Ventures.
Transaction Overview
Company Name
Announced On
4/23/2020
Transaction Type
Venture Equity
Amount
$1,000,000
Round
Seed
Investors
CureDuchenne Ventures (Debra Miller)
Proceeds Purpose
Myosana will use this initial funding to advance development of its innovative non-viral gene therapy to deliver full length dystrophin for Duchenne muscular dystrophy (DMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2617 Nw 59th St. 102
Seattle, WA 98107
USA
Seattle, WA 98107
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Myosana Therapeutics, Inc. is leading the efforts in developing new gene therapies that will slow skeletal muscle degeneration and heart failure to improve the quality of life, increase longevity and reduce the disease burden of Duchenne muscular dystrophy (DMD) and other neuromuscular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Stan Froehner
Chief Executive Officer
Steve Runnels
Chief Scientific Officer
Nick Whitehead
VP - R & D
Min Kim
Browse more venture capital transactions:
Prev: 4/23/2020: Hone venture capital transaction
Next: 4/23/2020: Bodhala venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs